INmune Bio Inc (INMB) - Cash Flow Conversion Efficiency
Based on the latest financial reports, INmune Bio Inc (INMB) has a cash flow conversion efficiency ratio of -0.323x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.58 Million) by net assets ($20.36 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market cap of INmune Bio Inc for the company's overall valuation and market capitalisation.
INmune Bio Inc - Cash Flow Conversion Efficiency Trend (2015–2025)
This chart illustrates how INmune Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
INmune Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of INmune Bio Inc ranked by their cash flow conversion efficiency. Explore INmune Bio Inc cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
MacroWell OMG Digital Entertainment Co Ltd
TWO:3687
|
0.021x |
|
Ma Kuang Healthcare Holding Ltd
TWO:4139
|
0.097x |
|
Sam-A Pharm. Co. Ltd
KQ:009300
|
0.001x |
|
Arlitech Electronic
TWO:6432
|
0.043x |
|
Chilwa Minerals Ltd
AU:CHW
|
-0.071x |
|
T7 Global Bhd
KLSE:7228
|
0.023x |
|
Univentures Public Company Limited
BK:UV
|
0.077x |
|
NTPM Holdings Bhd
KLSE:5066
|
0.027x |
Annual Cash Flow Conversion Efficiency for INmune Bio Inc (2015–2025)
The table below shows the annual cash flow conversion efficiency of INmune Bio Inc from 2015 to 2025. View INMB stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $23.52 Million | $-22.58 Million | -0.960x | +7.64% |
| 2024-12-31 | $32.10 Million | $-33.36 Million | -1.039x | -230.89% |
| 2023-12-31 | $38.14 Million | $-11.98 Million | -0.314x | +16.78% |
| 2022-12-31 | $60.10 Million | $-22.69 Million | -0.377x | -6.23% |
| 2021-12-31 | $80.22 Million | $-28.50 Million | -0.355x | -53.96% |
| 2020-12-31 | $38.75 Million | $-8.94 Million | -0.231x | -1.19% |
| 2019-12-31 | $23.61 Million | $-5.38 Million | -0.228x | -83.20% |
| 2018-12-31 | $16.54 Million | $-2.06 Million | -0.124x | -195.83% |
| 2017-12-31 | $18.10 Million | $-761.83K | -0.042x | -101.98% |
| 2016-12-31 | $-149.20K | $-317.38K | 2.127x | +121.52% |
| 2015-12-31 | $-18.87K | $-18.12K | 0.960x | -- |
About INmune Bio Inc
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of pati… Read more